[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |
Advanced search

EMEA (Europe, Middle East and Africa) Pulmonary Arterial Hypertension (PAH) Drugs Market Report 2017

August 2017 | 117 pages | ID: E2478E83ACCEN
QYResearch

US$ 4,000.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
In this report, the EMEA Pulmonary Arterial Hypertension (PAH) Drugs market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report split EMEA into Europe, the Middle East and Africa, With sales (K Units), revenue (Million USD), market share and growth rate of Pulmonary Arterial Hypertension (PAH) Drugs for these regions, from 2012 to 2022 (forecast)
  • Europe: Germany, France, UK, Russia, Italy and Benelux;
  • Middle East: Saudi Arabia, Israel, UAE and Iran;
  • Africa: South Africa, Nigeria, Egypt and Algeria.
EMEA Pulmonary Arterial Hypertension (PAH) Drugs market competition by top manufacturers/players, with Pulmonary Arterial Hypertension (PAH) Drugs sales volume (K Units), price (USD/Unit), revenue (Million USD) and market share for each manufacturer/player; the top players including
  • Actelion Pharmaceuticals
  • DAIICHI SANKYO
  • GlaxoSmithKline
  • Novartis
  • United Therapeutics
  • AADi
  • Actelion Pharmaceuticals
  • Aires Pharmaceuticals
  • Arena Pharmaceuticals
  • Asklepion Pharmaceuticals
  • AstraZeneca
  • Bayer Healthcare
  • Berlin Cures
  • BIAL
  • Eiger BioPharmaceuticals
On the basis of product, this report displays the sales volume (K Units), revenue (Million USD), product price (USD/Unit), market share and growth rate of each type, primarily split into
  • Inhalation
  • Injectables
  • Oral administration
On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume (K Units), market share and growth rate of Pulmonary Arterial Hypertension (PAH) Drugs for each application, including
  • ERAs
  • Prostacyclin analogs
  • PDE inhibitors
  • sGC stimulators
EMEA (Europe, Middle East and Africa) Pulmonary Arterial Hypertension (PAH) Drugs Market Report 2017

1 PULMONARY ARTERIAL HYPERTENSION (PAH) DRUGS OVERVIEW

1.1 Product Overview and Scope of Pulmonary Arterial Hypertension (PAH) Drugs
1.2 Classification of Pulmonary Arterial Hypertension (PAH) Drugs
  1.2.1 EMEA Pulmonary Arterial Hypertension (PAH) Drugs Market Size (Sales) Comparison by Type (2012-2022)
  1.2.2 EMEA Pulmonary Arterial Hypertension (PAH) Drugs Market Size (Sales) Market Share by Type (Product Category) in 2016
  1.2.3 Inhalation
  1.2.4 Injectables
  1.2.5 Oral administration
1.3 EMEA Pulmonary Arterial Hypertension (PAH) Drugs Market by Application/End Users
  1.3.1 EMEA Pulmonary Arterial Hypertension (PAH) Drugs Sales (Volume) and Market Share Comparison by Application (2012-2022
  1.3.2 ERAs
  1.3.3 Prostacyclin analogs
  1.3.4 PDE inhibitors
  1.3.5 sGC stimulators
1.4 EMEA Pulmonary Arterial Hypertension (PAH) Drugs Market by Region
  1.4.1 EMEA Pulmonary Arterial Hypertension (PAH) Drugs Market Size (Value) Comparison by Region (2012-2022)
  1.4.2 Europe Status and Prospect (2012-2022)
  1.4.3 Middle East Status and Prospect (2012-2022)
  1.4.4 Africa Status and Prospect (2012-2022)
1.5 EMEA Market Size (Value and Volume) of Pulmonary Arterial Hypertension (PAH) Drugs (2012-2022)
  1.5.1 EMEA Pulmonary Arterial Hypertension (PAH) Drugs Sales and Growth Rate (2012-2022)
  1.5.2 EMEA Pulmonary Arterial Hypertension (PAH) Drugs Revenue and Growth Rate (2012-2022)

2 EMEA PULMONARY ARTERIAL HYPERTENSION (PAH) DRUGS COMPETITION BY MANUFACTURERS/PLAYERS/SUPPLIERS, REGION, TYPE AND APPLICATION

2.1 EMEA Pulmonary Arterial Hypertension (PAH) Drugs Market Competition by Players/Manufacturers
  2.1.1 EMEA Pulmonary Arterial Hypertension (PAH) Drugs Sales Volume and Market Share of Major Players (2012-2017)
  2.1.2 EMEA Pulmonary Arterial Hypertension (PAH) Drugs Revenue and Share by Players (2012-2017)
  2.1.3 EMEA Pulmonary Arterial Hypertension (PAH) Drugs Sale Price by Players (2012-2017)
2.2 EMEA Pulmonary Arterial Hypertension (PAH) Drugs (Volume and Value) by Type/Product Category
  2.2.1 EMEA Pulmonary Arterial Hypertension (PAH) Drugs Sales and Market Share by Type (2012-2017)
  2.2.2 EMEA Pulmonary Arterial Hypertension (PAH) Drugs Revenue and Market Share by Type (2012-2017)
  2.2.3 EMEA Pulmonary Arterial Hypertension (PAH) Drugs Sale Price by Type (2012-2017)
2.3 EMEA Pulmonary Arterial Hypertension (PAH) Drugs (Volume) by Application
2.4 EMEA Pulmonary Arterial Hypertension (PAH) Drugs (Volume and Value) by Region
  2.4.1 EMEA Pulmonary Arterial Hypertension (PAH) Drugs Sales and Market Share by Region (2012-2017)
  2.4.2 EMEA Pulmonary Arterial Hypertension (PAH) Drugs Revenue and Market Share by Region (2012-2017)
  2.4.3 EMEA Pulmonary Arterial Hypertension (PAH) Drugs Sales Price by Region (2012-2017)

3 EUROPE PULMONARY ARTERIAL HYPERTENSION (PAH) DRUGS (VOLUME, VALUE AND SALES PRICE), BY PLAYERS, COUNTRIES, TYPE AND APPLICATION

3.1 Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales and Value (2012-2017)
  3.1.1 Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales Volume and Growth Rate (2012-2017)
  3.1.2 Europe Pulmonary Arterial Hypertension (PAH) Drugs Revenue and Growth Rate (2012-2017)
3.2 Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales and Market Share by Type
3.3 Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales and Market Share by Application
3.4 Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales Volume and Value (Revenue) by Countries
  3.4.1 Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales Volume by Countries (2012-2017)
  3.4.2 Europe Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Countries (2012-2017)
  3.4.3 Germany Pulmonary Arterial Hypertension (PAH) Drugs Sales and Growth Rate (2012-2017)
  3.4.4 France Pulmonary Arterial Hypertension (PAH) Drugs Sales and Growth Rate (2012-2017)
  3.4.5 UK Pulmonary Arterial Hypertension (PAH) Drugs Sales and Growth Rate (2012-2017)
  3.4.6 Russia Pulmonary Arterial Hypertension (PAH) Drugs Sales and Growth Rate (2012-2017)
  3.4.7 Italy Pulmonary Arterial Hypertension (PAH) Drugs Sales and Growth Rate (2012-2017)
  3.4.8 Benelux Pulmonary Arterial Hypertension (PAH) Drugs Sales and Growth Rate (2012-2017)

4 MIDDLE EAST PULMONARY ARTERIAL HYPERTENSION (PAH) DRUGS (VOLUME, VALUE AND SALES PRICE), BY REGION, TYPE AND APPLICATION

4.1 Middle East Pulmonary Arterial Hypertension (PAH) Drugs Sales and Value (2012-2017)
  4.1.1 Middle East Pulmonary Arterial Hypertension (PAH) Drugs Sales Volume and Growth Rate (2012-2017)
  4.1.2 Middle East Pulmonary Arterial Hypertension (PAH) Drugs Revenue and Growth Rate (2012-2017)
4.2 Middle East Pulmonary Arterial Hypertension (PAH) Drugs Sales and Market Share by Type
4.3 Middle East Pulmonary Arterial Hypertension (PAH) Drugs Sales and Market Share by Application
4.4 Middle East Pulmonary Arterial Hypertension (PAH) Drugs Sales Volume and Value (Revenue) by Countries
  4.4.1 Middle East Pulmonary Arterial Hypertension (PAH) Drugs Sales Volume by Countries (2012-2017)
  4.4.2 Middle East Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Countries (2012-2017)
  4.4.3 Saudi Arabia Pulmonary Arterial Hypertension (PAH) Drugs Sales and Growth Rate (2012-2017)
  4.4.4 Israel Pulmonary Arterial Hypertension (PAH) Drugs Sales and Growth Rate (2012-2017)
  4.4.5 UAE Pulmonary Arterial Hypertension (PAH) Drugs Sales and Growth Rate (2012-2017)
  4.4.6 Iran Pulmonary Arterial Hypertension (PAH) Drugs Sales and Growth Rate (2012-2017)

5 AFRICA PULMONARY ARTERIAL HYPERTENSION (PAH) DRUGS (VOLUME, VALUE AND SALES PRICE) BY PLAYERS, COUNTRIES, TYPE AND APPLICATION

5.1 Africa Pulmonary Arterial Hypertension (PAH) Drugs Sales and Value (2012-2017)
  5.1.1 Africa Pulmonary Arterial Hypertension (PAH) Drugs Sales Volume and Growth Rate (2012-2017)
  5.1.2 Africa Pulmonary Arterial Hypertension (PAH) Drugs Revenue and Growth Rate (2012-2017)
5.2 Africa Pulmonary Arterial Hypertension (PAH) Drugs Sales and Market Share by Type
5.3 Africa Pulmonary Arterial Hypertension (PAH) Drugs Sales and Market Share by Application
5.4 Africa Pulmonary Arterial Hypertension (PAH) Drugs Sales Volume and Value (Revenue) by Countries
  5.4.1 Africa Pulmonary Arterial Hypertension (PAH) Drugs Sales Volume by Countries (2012-2017)
  5.4.2 Africa Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Countries (2012-2017)
  5.4.3 South Africa Pulmonary Arterial Hypertension (PAH) Drugs Sales and Growth Rate (2012-2017)
  5.4.4 Nigeria Pulmonary Arterial Hypertension (PAH) Drugs Sales and Growth Rate (2012-2017)
  5.4.5 Egypt Pulmonary Arterial Hypertension (PAH) Drugs Sales and Growth Rate (2012-2017)
  5.4.6 Algeria Pulmonary Arterial Hypertension (PAH) Drugs Sales and Growth Rate (2012-2017)

6 EMEA PULMONARY ARTERIAL HYPERTENSION (PAH) DRUGS MANUFACTURERS/PLAYERS PROFILES AND SALES DATA

6.1 Actelion Pharmaceuticals
  6.1.1 Company Basic Information, Manufacturing Base and Competitors
  6.1.2 Pulmonary Arterial Hypertension (PAH) Drugs Product Type, Application and Specification
    6.1.2.1 Product A
    6.1.2.2 Product B
  6.1.3 Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.1.4 Main Business/Business Overview
6.2 DAIICHI SANKYO
  6.2.1 Company Basic Information, Manufacturing Base and Competitors
  6.2.2 Pulmonary Arterial Hypertension (PAH) Drugs Product Type, Application and Specification
    6.2.2.1 Product A
    6.2.2.2 Product B
  6.2.3 DAIICHI SANKYO Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.2.4 Main Business/Business Overview
6.3 GlaxoSmithKline
  6.3.1 Company Basic Information, Manufacturing Base and Competitors
  6.3.2 Pulmonary Arterial Hypertension (PAH) Drugs Product Type, Application and Specification
    6.3.2.1 Product A
    6.3.2.2 Product B
  6.3.3 GlaxoSmithKline Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.3.4 Main Business/Business Overview
6.4 Novartis
  6.4.1 Company Basic Information, Manufacturing Base and Competitors
  6.4.2 Pulmonary Arterial Hypertension (PAH) Drugs Product Type, Application and Specification
    6.4.2.1 Product A
    6.4.2.2 Product B
  6.4.3 Novartis Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.4.4 Main Business/Business Overview
6.5 United Therapeutics
  6.5.1 Company Basic Information, Manufacturing Base and Competitors
  6.5.2 Pulmonary Arterial Hypertension (PAH) Drugs Product Type, Application and Specification
    6.5.2.1 Product A
    6.5.2.2 Product B
  6.5.3 United Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.5.4 Main Business/Business Overview
6.6 AADi
  6.6.1 Company Basic Information, Manufacturing Base and Competitors
  6.6.2 Pulmonary Arterial Hypertension (PAH) Drugs Product Type, Application and Specification
    6.6.2.1 Product A
    6.6.2.2 Product B
  6.6.3 AADi Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.6.4 Main Business/Business Overview
6.7 Actelion Pharmaceuticals
  6.7.1 Company Basic Information, Manufacturing Base and Competitors
  6.7.2 Pulmonary Arterial Hypertension (PAH) Drugs Product Type, Application and Specification
    6.7.2.1 Product A
    6.7.2.2 Product B
  6.7.3 Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.7.4 Main Business/Business Overview
6.8 Aires Pharmaceuticals
  6.8.1 Company Basic Information, Manufacturing Base and Competitors
  6.8.2 Pulmonary Arterial Hypertension (PAH) Drugs Product Type, Application and Specification
    6.8.2.1 Product A
    6.8.2.2 Product B
  6.8.3 Aires Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.8.4 Main Business/Business Overview
6.9 Arena Pharmaceuticals
  6.9.1 Company Basic Information, Manufacturing Base and Competitors
  6.9.2 Pulmonary Arterial Hypertension (PAH) Drugs Product Type, Application and Specification
    6.9.2.1 Product A
    6.9.2.2 Product B
  6.9.3 Arena Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.9.4 Main Business/Business Overview
6.10 Asklepion Pharmaceuticals
  6.10.1 Company Basic Information, Manufacturing Base and Competitors
  6.10.2 Pulmonary Arterial Hypertension (PAH) Drugs Product Type, Application and Specification
    6.10.2.1 Product A
    6.10.2.2 Product B
  6.10.3 Asklepion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.10.4 Main Business/Business Overview
6.11 AstraZeneca
6.12 Bayer Healthcare
6.13 Berlin Cures
6.14 BIAL
6.15 Eiger BioPharmaceuticals

7 PULMONARY ARTERIAL HYPERTENSION (PAH) DRUGS MANUFACTURING COST ANALYSIS

7.1 Pulmonary Arterial Hypertension (PAH) Drugs Key Raw Materials Analysis
  7.1.1 Key Raw Materials
  7.1.2 Price Trend of Key Raw Materials
  7.1.3 Key Suppliers of Raw Materials
  7.1.4 Market Concentration Rate of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
  7.2.1 Raw Materials
  7.2.2 Labor Cost
  7.2.3 Manufacturing Expenses
7.3 Manufacturing Process Analysis of Pulmonary Arterial Hypertension (PAH) Drugs

8 INDUSTRIAL CHAIN, SOURCING STRATEGY AND DOWNSTREAM BUYERS

8.1 Pulmonary Arterial Hypertension (PAH) Drugs Industrial Chain Analysis
8.2 Upstream Raw Materials Sourcing
8.3 Raw Materials Sources of Pulmonary Arterial Hypertension (PAH) Drugs Major Manufacturers in 2016
8.4 Downstream Buyers

9 MARKETING STRATEGY ANALYSIS, DISTRIBUTORS/TRADERS

9.1 Marketing Channel
  9.1.1 Direct Marketing
  9.1.2 Indirect Marketing
  9.1.3 Marketing Channel Development Trend
9.2 Market Positioning
  9.2.1 Pricing Strategy
  9.2.2 Brand Strategy
  9.2.3 Target Client
9.3 Distributors/Traders List

10 MARKET EFFECT FACTORS ANALYSIS

10.1 Technology Progress/Risk
  10.1.1 Substitutes Threat
  10.1.2 Technology Progress in Related Industry
10.2 Consumer Needs/Customer Preference Change
10.3 Economic/Political Environmental Change

11 EMEA PULMONARY ARTERIAL HYPERTENSION (PAH) DRUGS MARKET FORECAST (2017-2022)

11.1 EMEA Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue and Price Forecast (2017-2022)
  11.1.1 EMEA Pulmonary Arterial Hypertension (PAH) Drugs Sales and Growth Rate Forecast (2017-2022)
  11.1.2 EMEA Pulmonary Arterial Hypertension (PAH) Drugs Revenue and Growth Rate Forecast (2017-2022)
  11.1.3 EMEA Pulmonary Arterial Hypertension (PAH) Drugs Price and Trend Forecast (2017-2022)
11.2 EMEA Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
11.3 Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
11.4 Middle Eastt Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
11.5 Africa Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
11.6 EMEA Pulmonary Arterial Hypertension (PAH) Drugs Sales Forecast by Type (2017-2022)
11.7 EMEA Pulmonary Arterial Hypertension (PAH) Drugs Sales Forecast by Application (2017-2022)

12 RESEARCH FINDINGS AND CONCLUSION

13 APPENDIX

13.1 Methodology/Research Approach
  13.1.1 Research Programs/Design
  13.1.2 Market Size Estimation
  13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
  13.2.1 Secondary Sources
  13.2.2 Primary Sources
13.3 Disclaimer


The report requires updating with new data and is sent in 2-3 business days after order is placed.
LIST OF TABLES AND FIGURES

Figure Product Picture of Pulmonary Arterial Hypertension (PAH) Drugs
Figure EMEA Pulmonary Arterial Hypertension (PAH) Drugs Sales Volume (K Units) by Type (2012-2022)
Figure EMEA Pulmonary Arterial Hypertension (PAH) Drugs Sales Volume Market Share by Type (Product Category) in 2016
Figure Inhalation Product Picture
Figure Injectables Product Picture
Figure Oral administration Product Picture
Figure EMEA Pulmonary Arterial Hypertension (PAH) Drugs Sales Volume (K Units) by Application (2012-2022)
Figure EMEA Sales Market Share of Pulmonary Arterial Hypertension (PAH) Drugs by Application in 2016
Figure ERAs Examples
Figure Prostacyclin analogs Examples
Figure PDE inhibitors Examples
Figure sGC stimulators Examples
Figure EMEA Pulmonary Arterial Hypertension (PAH) Drugs Market Size (Million USD) by Region (2012-2022)
Figure Europe Pulmonary Arterial Hypertension (PAH) Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure Europe Pulmonary Arterial Hypertension (PAH) Drugs Revenue (Million USD) Status and Forecast by Countries
Figure Middle East Pulmonary Arterial Hypertension (PAH) Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure Middle East Pulmonary Arterial Hypertension (PAH) Drugs Revenue (Million USD) Status and Forecast by Countries
Figure Africa Pulmonary Arterial Hypertension (PAH) Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure Africa Pulmonary Arterial Hypertension (PAH) Drugs Revenue (Million USD) Status and Forecast by Countries
Figure EMEA Pulmonary Arterial Hypertension (PAH) Drugs Sales Volume and Growth Rate (2012-2022)
Figure EMEA Pulmonary Arterial Hypertension (PAH) Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure EMEA Pulmonary Arterial Hypertension (PAH) Drugs Market Major Players Product Sales Volume (K Units) (2012-2017)
Table EMEA Pulmonary Arterial Hypertension (PAH) Drugs Sales Volume (K Units) of Major Players (2012-2017)
Table EMEA Pulmonary Arterial Hypertension (PAH) Drugs Sales Share by Players (2012-2017)
Figure 2016 Pulmonary Arterial Hypertension (PAH) Drugs Sales Share by Players
Figure 2017 Pulmonary Arterial Hypertension (PAH) Drugs Sales Share by Players
Figure EMEA Pulmonary Arterial Hypertension (PAH) Drugs Market Major Players Product Revenue (Million USD) (2012-2017)
Table EMEA Pulmonary Arterial Hypertension (PAH) Drugs Revenue (Million USD) by Players (2012-2017)
Table EMEA Pulmonary Arterial Hypertension (PAH) Drugs Revenue Share by Players (2012-2017)
Table 2016 EMEA Pulmonary Arterial Hypertension (PAH) Drugs Revenue Share by Players
Table 2017 EMEA Pulmonary Arterial Hypertension (PAH) Drugs Revenue Share by Players
Table EMEA Pulmonary Arterial Hypertension (PAH) Drugs Sale Price (USD/Unit) by Players (2012-2017)
Table EMEA Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Units) and Market Share by Type (2012-2017)
Table EMEA Pulmonary Arterial Hypertension (PAH) Drugs Sales Share by Type (2012-2017)
Figure Sales Market Share of Pulmonary Arterial Hypertension (PAH) Drugs by Type (2012-2017)
Figure EMEA Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Type (2012-2017)
Table EMEA Pulmonary Arterial Hypertension (PAH) Drugs Revenue (Million USD) and Market Share by Type (2012-2017)
Table EMEA Pulmonary Arterial Hypertension (PAH) Drugs Revenue Share by Type (2012-2017)
Figure Revenue Market Share of Pulmonary Arterial Hypertension (PAH) Drugs by Type in 2016
Table EMEA Pulmonary Arterial Hypertension (PAH) Drugs Sale Price (USD/Unit) by Type (2012-2017)
Table EMEA Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Units) and Market Share by Application (2012-2017)
Table EMEA Pulmonary Arterial Hypertension (PAH) Drugs Sales Share by Application (2012-2017)
Figure Sales Market Share of Pulmonary Arterial Hypertension (PAH) Drugs by Application (2012-2017)
Figure EMEA Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Application in 2016
Table EMEA Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Units) and Market Share by Region (2012-2017)
Table EMEA Pulmonary Arterial Hypertension (PAH) Drugs Sales Share by Region (2012-2017)
Figure Sales Market Share of Pulmonary Arterial Hypertension (PAH) Drugs by Region (2012-2017)
Figure EMEA Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share in 2016
Table EMEA Pulmonary Arterial Hypertension (PAH) Drugs Revenue (Million USD) and Market Share by Region (2012-2017)
Table EMEA Pulmonary Arterial Hypertension (PAH) Drugs Revenue Share by Region (2012-2017)
Figure Revenue Market Share of Pulmonary Arterial Hypertension (PAH) Drugs by Region (2012-2017)
Figure EMEA Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share Regions in 2016
Table EMEA Pulmonary Arterial Hypertension (PAH) Drugs Sales Price (USD/Unit) by Region (2012-2017)
Figure Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure Europe Pulmonary Arterial Hypertension (PAH) Drugs Revenue and Growth Rate (2012-2017)
Table Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Units) by Type (2012-2017)
Table Europe Pulmonary Arterial Hypertension (PAH) Drugs Market Share by Type (2012-2017)
Figure Europe Pulmonary Arterial Hypertension (PAH) Drugs Market Share by Type in 2016
Table Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Units) by Application (2012-2017)
Table Europe Pulmonary Arterial Hypertension (PAH) Drugs Market Share by Application (2012-2017)
Figure Europe Pulmonary Arterial Hypertension (PAH) Drugs Market Share by Application in 2016
Table Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Units) by Countries (2012-2017)
Table Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Countries (2012-2017)
Figure Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Countries (2012-2017)
Figure Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Countries in 2016
Table Europe Pulmonary Arterial Hypertension (PAH) Drugs Revenue (Million USD) by Countries (2012-2017)
Table Europe Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share by Countries (2012-2017)
Figure Europe Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share by Countries (2012-2017)
Figure Europe Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share by Countries in 2016
Figure Germany Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure France Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure UK Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure Russia Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure Italy Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure Benelux Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure Middle East Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure Middle East Pulmonary Arterial Hypertension (PAH) Drugs Revenue (Million USD) and Growth Rate (2012-2017)
Table Middle East Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Units) by Type (2012-2017)
Table Middle East Pulmonary Arterial Hypertension (PAH) Drugs Market Share by Type (2012-2017)
Figure Middle East Pulmonary Arterial Hypertension (PAH) Drugs Market Share by Type (2012-2017)
Table Middle East Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Units) by Applications (2012-2017)
Table Middle East Pulmonary Arterial Hypertension (PAH) Drugs Market Share by Applications (2012-2017)
Figure Middle East Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Application in 2016
Table Middle East Pulmonary Arterial Hypertension (PAH) Drugs Sales Volume (K Units) by Countries (2012-2017)
Table Middle East Pulmonary Arterial Hypertension (PAH) Drugs Sales Volume Market Share by Countries (2012-2017)
Figure Middle East Pulmonary Arterial Hypertension (PAH) Drugs Sales Volume Market Share by Countries in 2016
Table Middle East Pulmonary Arterial Hypertension (PAH) Drugs Revenue (Million USD) by Countries (2012-2017)
Table Middle East Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share by Countries (2012-2017)
Figure Middle East Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share by Countries (2012-2017)
Figure Middle East Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share by Countries in 2016
Figure Saudi Arabia Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure Israel Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure UAE Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure Iran Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure Africa Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure Africa Pulmonary Arterial Hypertension (PAH) Drugs Revenue (Million USD) and Growth Rate (2012-2017)
Table Africa Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Units) by Type (2012-2017)
Table Africa Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Type (2012-2017)
Figure Africa Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Type (2012-2017)
Figure Africa Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Type in 2016
Table Africa Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Units) by Application (2012-2017)
Table Africa Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Application (2012-2017)
Figure Africa Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Application (2012-2017)
Table Africa Pulmonary Arterial Hypertension (PAH) Drugs Sales Volume (K Units) by Countries (2012-2017)
Table Africa Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Countries (2012-2017)
Figure Africa Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Countries (2012-2017)
Figure Africa Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Countries in 2016
Table Africa Pulmonary Arterial Hypertension (PAH) Drugs Revenue (Million USD) by Countries (2012-2017)
Table Africa Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share by Countries (2012-2017)
Figure Africa Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share by Countries (2012-2017)
Figure Africa Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share by Countries in 2016
Figure South Africa Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure Nigeria Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure Egypt Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure Algeria Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Units) and Growth Rate (2012-2017)
Table Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Basic Information List
Table Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share in EMEA (2012-2017)
Figure Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share in EMEA (2012-2017)
Table DAIICHI SANKYO Pulmonary Arterial Hypertension (PAH) Drugs Basic Information List
Table DAIICHI SANKYO Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure DAIICHI SANKYO Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure DAIICHI SANKYO Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share in EMEA (2012-2017)
Figure DAIICHI SANKYO Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share in EMEA (2012-2017)
Table GlaxoSmithKline Pulmonary Arterial Hypertension (PAH) Drugs Basic Information List
Table GlaxoSmithKline Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure GlaxoSmithKline Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure GlaxoSmithKline Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share in EMEA (2012-2017)
Figure GlaxoSmithKline Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share in EMEA (2012-2017)
Table Novartis Pulmonary Arterial Hypertension (PAH) Drugs Basic Information List
Table Novartis Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Novartis Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure Novartis Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share in EMEA (2012-2017)
Figure Novartis Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share in EMEA (2012-2017)
Table United Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Basic Information List
Table United Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure United Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure United Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share in EMEA (2012-2017)
Figure United Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share in EMEA (2012-2017)
Table AADi Pulmonary Arterial Hypertension (PAH) Drugs Basic Information List
Table AADi Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure AADi Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure AADi Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share in EMEA (2012-2017)
Figure AADi Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share in EMEA (2012-2017)
Table Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Basic Information List
Table Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share in EMEA (2012-2017)
Figure Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share in EMEA (2012-2017)
Table Aires Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Basic Information List
Table Aires Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Aires Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure Aires Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share in EMEA (2012-2017)
Figure Aires Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share in EMEA (2012-2017)
Table Arena Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Basic Information List
Table Arena Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Arena Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure Arena Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share in EMEA (2012-2017)
Figure Arena Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share in EMEA (2012-2017)
Table Asklepion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Basic Information List
Table Asklepion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Asklepion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Units) and Growth Rate (2012-2017)
Figure Asklepion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share in EMEA (2012-2017)
Figure Asklepion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share in EMEA (2012-2017)
Table AstraZeneca Pulmonary Arterial Hypertension (PAH) Drugs Basic Information List
Table Bayer Healthcare Pulmonary Arterial Hypertension (PAH) Drugs Basic Information List
Table Berlin Cures Pulmonary Arterial Hypertension (PAH) Drugs Basic Information List
Table BIAL Pulmonary Arterial Hypertension (PAH) Drugs Basic Information List
Table Eiger BioPharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Basic Information List
Table Production Base and Market Concentration Rate of Raw Material
Figure Price Trend of Key Raw Materials
Table Key Suppliers of Raw Materials
Figure Manufacturing Cost Structure of Pulmonary Arterial Hypertension (PAH) Drugs
Figure Manufacturing Process Analysis of Pulmonary Arterial Hypertension (PAH) Drugs
Figure Pulmonary Arterial Hypertension (PAH) Drugs Industrial Chain Analysis
Table Raw Materials Sources of Pulmonary Arterial Hypertension (PAH) Drugs Major Manufacturers in 2016
Table Major Buyers of Pulmonary Arterial Hypertension (PAH) Drugs
Table Distributors/Traders List
Figure EMEA Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Units) and Growth Rate Forecast (2017-2022)
Figure EMEA Pulmonary Arterial Hypertension (PAH) Drugs Revenue and Growth Rate Forecast (2017-2022)
Figure EMEA Pulmonary Arterial Hypertension (PAH) Drugs Price (USD/Unit) and Trend Forecast (2017-2022)
Table EMEA Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Units) Forecast by Region (2017-2022)
Figure EMEA Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share Forecast by Region (2017-2022)
Table EMEA Pulmonary Arterial Hypertension (PAH) Drugs Revenue (Million USD) Forecast by Region (2017-2022)
Figure EMEA Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share Forecast by Region (2017-2022)
Table Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Units) Forecast by Countries (2017-2022)
Figure Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share Forecast by Countries (2017-2022)
Table Europe Pulmonary Arterial Hypertension (PAH) Drugs Revenue (Million USD) Forecast by Countries (2017-2022)
Figure Europe Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share Forecast by Countries (2017-2022)
Table Middle East Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Units) Forecast by Countries (2017-2022)
Figure Middle East Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share Forecast by Countries (2017-2022)
Table Middle East Pulmonary Arterial Hypertension (PAH) Drugs Revenue (Million USD) Forecast by Countries (2017-2022)
Figure Middle East Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share Forecast by Countries (2017-2022)
Table Africa Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Units) Forecast by Countries (2017-2022)
Figure Africa Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share Forecast by Countries (2017-2022)
Table Africa Pulmonary Arterial Hypertension (PAH) Drugs Revenue (Million USD) Forecast by Countries (2017-2022)
Figure Africa Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share Forecast by Countries (2017-2022)
Table EMEA Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Units) Forecast by Type (2017-2022)
Figure EMEA Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share Forecast by Type (2017-2022)
Table EMEA Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Units) Forecast by Application (2017-2022)
Figure EMEA Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share Forecast by Application (2017-2022)
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources

More Publications

Need Help?

Ask a Question

Market Reports

All Categories